Cartikeya Reddy - Dr Reddys Senior Vice President Head - Biologics

<div class='logoBackup' style='background:#754DEB;color: white;font-size:4em;padding-top: 15px;;'>DR</div>
RDY -- USA Stock  

USD 41.59  0.86  2.03%

  President
Dr. Cartikeya Reddy serves as an Executive Vice President and HeadBiologics of Dr. Reddy Laboratories Ltd. He focuses on the development of biosimilar molecules for the Indian and global markets. Prior to joining in 2004, Mr. Reddy worked with Genentech Inc., where he was a Group Leader in the area of Cell Culture Process Development. Before that, he was with the Biotechnology Division of Bayer Corporationrationration, where he led teams in the areas of Bioprocess Development and pilot scale manufacturing
Age: 46  President Since 2016      
91 40 4900 2900  http://www.drreddys.com
Reddy holds a MS degree and Ph.D. in Chemical Engineering from the University of Illinois, UrbanaChampaign, and was a Visiting Scholar at the Massachusetts Institute of Technology in Cambridge, Massachusetts, United States of America. He also graduated with a Bachelor of Technology degree in Chemical Engineering from the Indian Institute of Technology in Chennai, India.

Management Efficiency

The company has Return on Asset of 6.98 % which means that on every $100 spent on asset it made $6.98 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.75 % implying that it generated $18.75 on every 100 dollars invested.
The company has 811.73 M in debt with debt to equity (D/E) ratio of 20.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.92 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Alejandro BernalZoetis
2015
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Christopher FenimoreRegeneron Pharmaceuticals
2017
Clinton LewisZoetis
2018
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Jay MarkowitzRegeneron Pharmaceuticals
2017
Roxanne LaganoZoetis
2015
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Ronald JanishPerrigo Company Plc
2015
John HendricksonPerrigo Company Plc
2016
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
Andrew FentonZoetis
2018
Douglas BoothePerrigo Company Plc
2013
Michael AbermanRegeneron Pharmaceuticals
2015
Peter PowchikRegeneron Pharmaceuticals
2006
Daniel PlewRegeneron Pharmaceuticals
2016
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Svend AndersenPerrigo Company Plc
2017
Joseph LaRosaRegeneron Pharmaceuticals
2019
Glenn DavidZoetis
2016

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

Did you try this?

Run Fundamentals Matrix Now

   

Fundamentals Matrix

View fundamentals matrix and analyze how accounts are interrelated and interconnected with each other
All  Next Launch Module

Currently Active Assets on Macroaxis

SSM   
Sold over 100K shares of
3 days ago
Traded for 0.175
S32   
Purchased over 10K shares of
3 days ago
Traded for 2.5
BSL   
Purchased over 100 shares of
3 days ago
Traded for 15.49
MBI   
Purchased over 100 shares of
few days ago
Traded for 9.2
MDLZ   
Purchased over 100 shares of
few days ago
Traded for 54.19
Additionally take a look at Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.